| Literature DB >> 29489842 |
Paryaneh Rostami1, Darren M Ashcroft1,2, Mary P Tully1,3.
Abstract
BACKGROUND: Reducing medication-related harm is a global priority; however, impetus for improvement is impeded as routine medication safety data are seldom available. Therefore, the Medication Safety Thermometer was developed within England's National Health Service. This study aimed to explore the implementation of the tool into routine practice from users' perspectives.Entities:
Mesh:
Year: 2018 PMID: 29489842 PMCID: PMC5830037 DOI: 10.1371/journal.pone.0192224
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Descriptive themes and their definitions.
| Normalisation process theory construct | Descriptive theme | Definition |
|---|---|---|
| Views on what the Medication Safety Thermometer is and how it should be used, as perceived by participants. | ||
| How the Medication Safety Thermometer data were being collected, which represents the understanding of the wider teams within organisations regarding how the Medication Safety Thermometer should be used. | ||
| The culture within organisations prior to using the tool, with respect to patient safety, auditing and quality improvement. | ||
| Ownership of medication safety overall and engagement with Medication Safety Thermometer data collection and use of data, for further improvement work. | ||
| Views on the impact of having individuals who lead implementation of the MedsST, and relevant support networks for those leading implementation and frontline users, at organisational, regional and national levels. | ||
| Actions taken, or planned, to scale up use of the tool. | ||
| Time and money as influences on collecting MedsST data and subsequent improvement work using the data | ||
| Details of associated training for staff involved with the use of the Medication Safety Thermometer | ||
| How the data were actually used within organisations. | ||
| Changes to the process of collecting Medication Safety Thermometer data to suit individual contexts. Including suggestions for the future. |
The co-authors contributed to the analysis in discussion of data, themes and constructs, to ensure that all perspectives were covered. Quotes were chosen to best illustrate each theme and to display a range of varying opinions. Words in parenthesis have been added to quotes by the authors to clarify meaning, and ellipses (…) have been used to indicate the removal of unrelated text or information that may lead to identification of participants. Participant details are presented in Table 2.
Participant details.
| Organisation | Participant | Implementation Role (Lead/User) | Profession | Setting Type |
|---|---|---|---|---|
| 1 (LA) | 1 | Lead | Pharmacist (MSO | Secondary care |
| 2 (LA) | 2 | Lead | Pharmacist (MSO) | Secondary care |
| 3 | User | Clinical Auditor | Secondary care | |
| 3 (LA) | 4 | Lead | Pharmacist | Primary care |
| 4 (LA) | 5 | User | Pharmacy Technician | Secondary care |
| 6 | Lead | Pharmacist (MSO) | Secondary care | |
| 5 (LA) | 7 | User | Pharmacist | Secondary care |
| 6 (EA) | 8 | Lead | Pharmacist (MSO) | Secondary care |
| 9 | User | Nurse | Secondary care | |
| 7 (EA) | 10 | User | Nurse | Secondary care |
| 11 | Lead | Pharmacist | Secondary care | |
| 8 (EA) | 12 | Lead | Pharmacist (MSO) | Secondary care |
| 13 | User | Nurse | Secondary care | |
| 9 (EA) | 14 | Lead | Pharmacist (MSO) | Primary care |
| 10 (EA) | 15 | User | Pre-registration Pharmacist | Secondary care |
*MSO: Medication Safety Officer. EA: Early adopter (joined in the alpha-testing phase [January–March 2013]). LA: Late Adopter (joined in the beta-testing phase or after [April 2013 onwards]) [2].